818.101.24
English is not an official language of the Swiss Confederation. This translation is provided for information purposes only, has no legal force and may not be relied on in legal proceedings.
of 19 June 2020 (Status as of 17 February 2022)
The Swiss Federal Council,
based on Articles 3, 4, 5 letters a and b and 8 of the COVID-19 Act of 25 September 20201, on Article 63 paragraph 3 of the Therapeutic Products Act of 15 December 20002, and on Article 41 paragraph 1 of the Epidemics Act of 28 September 20123 (EpidA),4
ordains:
4 Amended by No I of the O of 19 March 2021 (Employees at High Risk - Extension), in force from 1 April 2021 (AS 2021 167).
1 This Ordinance orders measures applicable to the population, organisations and institutions and the cantons to combat the coronavirus (COVID-19).
2 The measures serve to ensure Switzerland’s capacities to manage the epidemic, in particular to maintain the provision of the population with adequate care and a sufficient supply of essential medical goods.
Unless this Ordinance provides otherwise, the cantons shall retain their responsibilities.
1 In order to maintain Switzerland’s capacities to manage the COVID-19 epidemic and in particular to guarantee the provision of the population with adequate care and a sufficient supply of essential medical products, the following measures in particular must be taken:
2 High-risk countries or regions are countries or regions in which the coronavirus Sars-CoV-2 has been detected and in which:
3 The lists of high-risk countries and regions is published in Annex 1.6
5 Amended by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
6 Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
1 The following persons shall be refused entry for a period of stay of up to three months that does not require a permit and does not involve gainful employment (Art. 10 of the Foreign Nationals and Integration Act of 16 December 20058 (FNIA):
2 The following persons are exempt from this ban on entry:
2bis Children under the age of 18 who enter Switzerland accompanied by an adult who meets the requirements of paragraph 2 letter a are not required to prove that they have been vaccinated.14
2ter The exception in paragraph 2 letter a does not apply to persons who wish to enter Switzerland from a country or region listed in Annex 1 number 2.15
2quater The State Secretariat for Migration (SEM) shall issue the required directives on exceptions to the ban on entry.16
3 Decisions taken by the competent authorities may be enforced immediately. Article 65 of the FNIA applies mutatis mutandis. An appeal may be filed against the SEM decision within 30 days of notification. The appeal does not have suspensive effect.
4 The criminal provisions of Article 115 FNIA apply mutatis mutandis. In the event of any violation of the provision on entry, a ban on entry may also be imposed.
7 Amended by No I of the O of 24 June 2020 (Relaxation of Measures relating to Borders, Entry and Admission for Residence and Employment), in force since 6 July 2020 (AS 2020 2611).
10 SR 0.632.31
11 Repealed by Annex 2 No 2 of the COVID-19 Ordinance on International Travel Measures of 27 Jan. 2021, with effect from 8 Feb. 2021 (AS 2021 61).
12 Amended by No I of the O of 21 Dec. 2020, in force since 21 Dec. 2020 at 1pm (AS 2020 6395).
13 Amended by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
14 Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
15 Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
16 Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
The Federal Department of Justice and Police (FDJP) shall update Annexes 1 and 1a continuously in consultation with the Federal Department of Home Affairs (FDHA) and the Federal Department of Foreign Affairs (FDFA).
17 Amended by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
18 Repealed by No I of the O of 24 June 2020 (Relaxation of Measures relating to Borders, Entry and Admission for Residence and Employment), with effect from 6 July 2020 (AS 2020 2611).
19 Repealed by Art. 6 No 1 of the COVID-19 Ordinance on International Travel Measures of 2 July 2020, with effect from 6 July 2020 (AS 2020 2737).
1 The FDJP in consultation with the FDHA, the Federal Department of the Environment, Transport, Energy and Communications (DETEC), the FDF and the FDFA shall decide on restrictions on air passenger services from high-risk countries or regions.
2 It may in particular suspend passenger movements for certain flights, close individual airfields with international borders to passenger movements from high-risk countries or regions or prohibit movements of persons to Switzerland from high-risk countries or regions entirely.
3 Restrictions on cross-border movements of persons are set out in Annex 2.
Foreign nationals who wish to enter Switzerland from a high-risk country or from a high-risk region and who do not fall within the scope of the AFMP21 or the EFTA Convention22 shall not be granted a Schengen visa for periods of stay of up to three months that do not require a permit and do not involve gainful employment. Exempted from the foregoing are applications from persons under Article 4 paragraphs 2 and 2bis.
20 Amended by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021, in force since 26 June 2021 (AS 2021 380).
22 SR 0.632.31
1 Foreign nationals who have been prevented from acting within the deadlines laid down in Articles 47 or 61 FNIA24 because of measures in connection with the coronavirus may carry out the act required at any time while this Ordinance remains in force.
2 By carrying out the required act, they shall achieve the position that would have been achieved had they acted within the prescribed deadline.
3 If the deadlines under Articles 59b or 102a FNIA for updating biometric data in order to obtain or extend a permit cannot be met because of the coronavirus, the permit may still be issued or extended at any time while this Ordinance remains in force.
23 Inserted by No I of the O of 24 June 2020 (Relaxation of Measures relating to Borders, Entry and Admission for Residence and Employment), in force since 6 July 2020 (AS 2020 2611).
24 SR 142.20
1 Medicinal products, medical devices and protective equipment (essential medical goods) that are important and urgently needed to prevent and combat the coronavirus (COVID-19) are the goods listed in Annex 4.
2 The Federal Department of Home Affairs (FDHA) is responsible for the list and shall update the same regularly in consultation with the Interdepartmental Working Group on Medical Goods in accordance with Article 12 and the Spiez Laboratory.25
3 The Federal Office of Public Health (FOPH) shall define the goods that need to be procured and how they should be used. Based on these terms of reference, the FOPH shall determine the quantities required in consultation with:26
25 Amended by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since 21 Dec. 2020 (AS 2020 5801).
26 Amended by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since 21 Dec. 2020 (AS 2020 5801).
1 The Interdepartmental Working Group on Medical Goods shall comprise as a minimum representatives from the following federal agencies:
2 The Federal Council CMS delegate chairs the working group.27
27 Amended by No I of the O of 12 May 2021, in force since 17 May 2021 (AS 2021 274).
1 The cantons are obliged on request to report to the CMS on the current stocks of essential medical goods in their healthcare facilities.
2 Laboratories and manufacturers and distributors of in vitro diagnostics (COVID-19 tests) are obliged to report regularly to the Spiez Laboratory on their current stocks of such tests.
3 The CMS may request details of stocks from companies that store essential medical goods.
1 In order to support the provision of essential medical goods to the cantons and their healthcare facilities, charitable organisations (for example Swiss Red Cross) and third parties (for example laboratories, pharmacies), essential medical goods may be procured if requirements cannot be covered through the normal procurement channels.
2 The essential medical goods that are required shall be determined on the basis of the data transmitted in accordance with Article 13.
3 The Armed Forces Pharmacy is responsible for procuring essential medical goods under paragraph 1 on behalf of the FOPH.
4 The responsible authorities may delegate the procurement of essential medical goods to third parties.
5 When procuring essential medical goods, the Armed Forces Pharmacy may take calculated risks and diverge from the provisions of existing directives and the Financial Budget Act of 7 October 200528 in relation to risks, such as prepayment without security or currency hedging.
6 The Armed Forces Pharmacy manages the procured essential medical goods as instructed by the Interdepartmental Working Group on Medical Goods.
28 SR 611.0
1 The cantons shall submit requests for allocation to the ResMaB as required.29
2 Allocation shall be made continuously based on the supply situation and the current number of cases in each canton.
3 The CMS in consultation with Interdepartmental Working Group on Medical Goods may allocate essential medical goods to the cantons, to charitable organisations and to third parties.
4 The Spiez Laboratory in consultation with the FOPH is responsible for allocating in vitro diagnostics (COVID-19 tests). Allocation when required applies to all tests available in Switzerland.
29 Amended by No I of the O of 12 May 2021, in force since 17 May 2021 (AS 2021 274).
1 The Confederation or the third parties that it instructs shall ensure the delivery of the essential medical goods procured under Article 14 to a distribution centre for each canton. In exceptional cases, the Confederation in consultation with the cantons may supply eligible facilities and organisations directly.
2 The cantons shall designate cantonal distribution centres for goods that are not supplied directly to the recipient, and shall give notice of these to the responsible federal authorities.
3 They shall ensure that essential medical goods that have been delivered are distributed as required and in good time on their territory.
The Confederation may sell the essential medical goods on the market in return for payment, either itself or through third parties.
1 The costs of procuring essential medical goods shall be funded in advance by the Confederation in the cases where it procures the goods.
2 The cantons, charitable organisations and third parties shall notify the Confederation as quickly as possible of the purchasing costs of the essential medical goods supplied to them where the Confederation has assumed responsibility for their procurement in accordance with Article 14 paragraph 1.
3 The Confederation shall bear the costs of delivering the procured essential medical goods to the cantons.
4 The cantons shall bear the costs of distributing these essential medical goods within the canton.
5 If the procured goods become freely available in the market again, the Confederation may sell its stocks at market prices.30
30 Inserted by No I of the O of 12 May 2021, in force since 17 May 2021 (AS 2021 274).
1 If the provision of essential medical goods cannot be guaranteed, the FDHA at the request of the Interdepartmental Working Group on Medical Goods may require individual cantons or public healthcare facilities that have adequate stocks of medicinal products under Annex 4 number 1 to deliver part of their stocks to other cantons or healthcare facilities. The cantons or healthcare facilities shall charge the recipient directly for the costs of the goods and their delivery at the sale price.
2 Subject to the requirement of paragraph 1, the FDHA at the request of the Interdepartmental Working Group on Medical Goods may order the requisitioning of essential medical goods held by companies. The Confederation shall pay compensation at the sale price.
1 If the provision of essential medical goods cannot otherwise be guaranteed, the Federal Council at the request of the Interdepartmental Working Group on Medical Goods may require manufacturers to produce essential medical goods, to prioritise the production of such goods or to increase production volumes.
2 The Confederation may contribute to the cost of production under paragraph 1 where manufacturers suffer financial disadvantages as a result of the changeover in production or the cancellation of private orders.
1 Medicinal products that are manufactured with active substances under Annex 5 for the treatment of COVID-19 patients may, provided an application for authorisation of a medicinal product containing one of these active substances has been filed, be placed on the market without authorisation pending Swissmedic’s decision on authorisation. When examining applications for authorisation, Swissmedic may permit a relaxation of the relevant requirements for such medicinal products under the law on therapeutic products on the basis of a risk-benefit analysis.
2 Amendments to the authorisation for a medicinal product authorised in Switzerland containing an active substance under Annex 4 number 1 on the basis of which the medicinal product can be used to treat COVID-19 patients in Switzerland may be made immediately after filing a corresponding amendment application and pending Swissmedic’s decision on authorisation. Swissmedic may, on the basis of a risk-benefit analysis, permit a relaxation of the relevant requirements under the law on therapeutic products for amendments to the authorisation of medicinal products containing an active substance listed in Annex 4 number 1.31
3 The FDHA shall regularly update the list in Annex 5.32
4 Swissmedic may on the basis of a risk-benefit analysis permit changes to the manufacturing process approved within the framework of the authorisation of medicinal products used to prevent and treat COVID-19 in Switzerland. It shall specify criteria according to which the person responsible for technical matters may grant an early market release for medicinal products used to prevent and treat COVID-19 in Switzerland.
5 In derogation from Article 9a paragraph 1 letter c of the Therapeutic Products Act of 15 December 2000, temporary authorisations may be issued even if an authorised equivalent medicinal product that can be used as an alternative is available in Switzerland, provided the authorisations serve to guarantee the supply of medicinal products to prevent and combat the coronavirus in Switzerland.33
31 Amended by No I of the O of 12 May 2021, in force since 17 May 2021 (AS 2021 274).
32 Amended by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since 21 Dec. 2020 (AS 2020 5801).
33 Inserted by No I of the O of 27 Oct. 2021, in force since 28 Oct. 2021 (AS 2021 634).
1 Following the submission of a authorisation application for a medicinal product containing active substances listed in Annex 5 for the treatment of Covid 19 patients, the applicant may import the medicinal product prior to its authorisation or entrust the import of the medicinal product to a company with a wholesale or import licence.34
1bis Pharmacists that have pharmaceutical responsibility in a hospital pharmacy may import non-authorised medicinal products with active substances under Annex 5 for the treatment of COVID-19 patients. A company with a wholesale or import licence may be instructed to import such medicinal products.35
2 Notice of each import under paragraph 1bis must be given to Swissmedic within 10 days of the arrival of goods.36
3 In order to prevent and treat COVID-19 in Switzerland, Swissmedic may allow the temporary placing on the market of a medicinal product as a short-term solution for the temporary non-availability of an identical medicinal product authorised in Switzerland, provided no essentially identical medicinal product is authorised and available in Switzerland.
4 After submitting its application for authorisation for a COVID-19 vaccine and for an operating licence under Article 10 paragraph 1 letter b of the Therapeutic Products Act of 15 December 2000, the applicant may instruct a company with a wholesale or import licence to import the COVID-19 vaccine before its authorisation and to store the vaccine until authorisation is granted. The company instructed must comply with the international rules on good distribution practice in accordance with Annex 4 of the Medicinal Products Licensing Ordinance of 14 November 201837.38
34 Inserted by No I of the O of 12 May 2021, in force since 26 April 2021 (AS 2021 274).
35 Originally para. 1.
36 Amended by No I of the O of 12 May 2021, in force since 26 April 2021 (AS 2021 274).
37 SR 812.212.1
38 Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since 21 Dec. 2020 (AS 2020 5801).
1 In response to an application, Swissmedic may authorise the placing on the market and use of medical devices that have not undergone a conformity assessment procedure in accordance with Article 23 the Medical Devices Ordinance of 1 July 20204041 (MedDO), provided their use for preventing and combating the coronavirus in Switzerland is in the interests of public health or patient safety or health and provided, taking account of their intended purpose, their fulfilment of the essential requirements and their effectiveness and performance are adequately proven.
2 When assessing the risks under paragraph 1, Swissmedic shall in particular take account of the procurement needs identified by the FOPH for preventing and combating the coronavirus in Switzerland.
3 Authorisation shall be granted to the Swiss distributor or the applicant institution or healthcare facility. It may be made subject to a time limit and other conditions and requirements.
4 Facemasks which have not undergone a conformity assessment procedure under Article 23 MedDO may be placed on the market without authorisation under paragraph 1 provided they:
5 Facemasks placed on the market in accordance with paragraph 3bis may not be used in hospitals or medical practices by persons in direct contact with patients.
5bis The SwissCovid app as specified in the Ordinance of 24 June 202042 on the Proximity Tracing System for the Coronavirus Sars-CoV-2 and as specified in the Ordinance of 30 June 202143 on a Notification System for possible Infection with the Coronavirus Sars-CoV-2 at Events is not subject to the provisions on the conformity assessment of medical devices.44
6 The obligations in relation to product surveillance under the MedDO, in particular to collecting reports of incidents, continue to apply.
39 Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
40 SR 812.213
41 The reference was amended on 26 May 2021 pursuant to Art. 12 para. 2 of the Publications Act of 18 June 2004 (SR 170.512). The amendment has been made throughout the text.
43 SR 818.102.4
44 Inserted by Art. 18 of the O of 30 June 2021 on a Notification System for possible Infection with the Coronavirus Sars-CoV-2 at Events, in force from 1 July 2021 until 30 June 2022 (AS 2021 411).
45 Inserted by No I of the O of 12 March 2021 (AS 2021 145). Repealed by No I of the O of 23 June 2021, with effect from 26 June 2021 (AS 2021 378).
1 FFP masks that do not comply with the principles and procedures for conformity assessment under Article 3 paragraph 2 of the PPE Ordinance of 25 October 201747 (PPEO) and whose non-compliance with these principles and procedure has not been approved based on Article 24 paragraph 3 in its version of 22 June 202048 may not be placed on the market.
2 FFP masks under paragraph 1 held in federal and cantonal stocks may be supplied to private hospitals, homes for the elderly and care homes and organisations that provide nursing services and other assistance at home as well as to federal and cantonal facilities such as the armed forces, civil defence units, hospitals and prisons provided the federal or cantonal authority responsible for the supply:
3 Product information in at least one official language or in English must be available when the masks are supplied. It must be ensured that the user is able to use the product in accordance with the relevant provisions.
46 Originally Art. 23a. Inserted by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks), in force since 28 Jan. 2021 (AS 2021 54).
47 SR 930.115
48 AS 2020 2195
1 Non-automated single-patient rapid tests for direct detection of Sars-CoV-2 (Sars-CoV-2 rapid tests) for specialist use may only be carried out in the following facilities:51
1bis They may also be carried out in and by organisations that provide nursing services and other assistance at home as well as by assistants as defined in the Federal Act of 19 June 195954 on Invalidity Insurance (InvIA).55
2 Sars-CoV-2 rapid tests may also be carried out at a location outside the facilities mentioned in paragraph 1 provided a laboratory manager, a doctor or a pharmacist accepts responsibility for complying with the requirements of this article and Articles 24a and 24b.56
3 If facilities under paragraph 1 letter a offer Sars-CoV-2 rapid tests at a location outside the facilities, they must notify the canton of their offer.57
4 Facilities under paragraphs 1 letter b and 1bis may carry out Sars-CoV-2 rapid tests for specialist use without a licence under Article 16 EpidA and outside closed systems provided they comply with the following conditions:58
4bis Sars-CoV-2 rapid tests for self-testing by the public (Sars-CoV-2 self-tests) may be supplied and used if they are intended for self-testing by the manufacturer and certified accordingly.60
5 Sars-CoV-2 rapid tests are direct detection methods that detect the antigens to Sars-CoV-2. The tests are not automated and are carried out with the minimum of instruments; only the reading of the test result may be automated.61
49 Amended by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since 21 Dec. 2020 (AS 2020 5801).
50 Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
51 Amended by No I of the O of 23 June 2021, in force since 26 June 2021 (AS 2021 378).
52 SR 818.101
53 Amended by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks), in force since 28 Jan. 2021 (AS 2021 54).
54 SR 831.20
55 Inserted by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks) (AS 2021 54). Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
56 Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
57 Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
58 Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
59 Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
60 Inserted by No I of the O of 12 March 2021 (AS 2021 145). Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
61 Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
1 The only test systems that may be used for Sars-CoV-2 rapid tests for specialist use are those authorised in the EU for issuing the EU’s digital COVID certificate.
2 In derogation from paragraph 1, other test systems may also be used provided the Sars-CoV-2 rapid tests are carried out by laboratories licensed under Article 16 EpidA and the sample collection stations that they operate.
62 Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (AS 2020 5801). Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
If no confirmatory diagnosis is made following a positive result for a Sars-CoV-2 rapid test and if the FDHA has not required a report on the result of Sars-CoV-2 rapid tests on the basis of Article 19 of the Epidemics Ordinance of 29 April 201564, the facility or person responsible for conducting the tests must notify the cantonal authority or organisation responsible for contact tracing of the positive test result.
63 Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (AS 2020 5801). Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
64 SR 818.101.1
The FOPH shall maintain continuously updated lists of Sars-CoV-2 rapid tests for specialist use in accordance with Article 24a and the Sars-CoV-2 self-tests in accordance with Article 24 paragraph 4bis and shall publish the lists on its website.
65 Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (AS 2020 5801). Amended by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
The cantons are responsible for monitoring and enforcing compliance with the conditions in Articles 24–24b for Sars-CoV-2 rapid tests that are not carried out at the facilities referred to in Article 24 paragraph 1 letter a.
66 Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (AS 2020 5801). Amended by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks), in force since 28 Jan. 2021 (AS 2021 54).
1 Samples for molecular-biological analyses for Sars-CoV-2 may be collected:
2 The sample collection station must verify the identity of the person being tested. The sample must be collected by a person trained for this purpose.
3 The sample may also be collected by the person being tested themselves:
67 Inserted by No I of the O of 25 Aug. 2021, in force since 1 Oct. 2021 (AS 2021 507).
Swissmedic is responsible for monitoring compliance with the requirements set out in Article 24e by laboratories licensed under Article 16 EpidA, including the collection of samples carried out under the supervision of such laboratories by facilities in accordance with Article 24e paragraph 1 letter c, and the cantons are responsible for monitoring in the facilities in accordance with Article 24e paragraph 1 letter b and for the supervision of collection stations in accordance with Article 24e paragraph 1 letter c.
68 Inserted by No I of the O of 25 Aug. 2021, in force since 1 Oct. 2021 (AS 2021 507).
Swissmedic may disclose data on essential medical goods to the federal offices and organisations mentioned in Article 12 paragraph 1, provided this is required in order to implement this Ordinance. The data must not include sensitive personal data.
69 Originally Art. 24e. Inserted by No I of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests), in force since 21 Dec. 2020 (AS 2020 5801).
1 The cantons shall ensure that sufficient capacities (in particular beds and specialist staff) are available in the inpatient departments of hospitals and clinics for COVID-19 patients and for other urgently required medical examinations and treatments, in particular in the intensive care units and the general internal medicine departments.
2 For this purpose, they may require hospitals and clinics:
3 The hospitals and clinics must ensure that supplies of medicinal products for COVID-19 patients and for other urgently required medical examinations and treatments is guaranteed in their outpatient and inpatient departments.
The cantons shall be required to report the following regularly to the Coordinated Medical Services:
70 Inserted by Annex No 2 of the COVID-19 Special Situation Ordinance of 16 Feb. 2022, in force since 17 Feb. 2022 (AS 2022 97).
1 The Confederation shall pay the effective costs of analyses for Sars-CoV-2 subject to the requirements and maximum amounts set out in Annex 6.72
2 Every week, the FOPH shall publish on its website the number of molecular-biological analyses for Sars-CoV-2 in accordance with Annex 6 number 1 that were conducted in the previous calendar week in Switzerland and in Liechtenstein. The FDHA may adjust the maximum amounts paid in line with the effective costs.
3 For analyses for Sars-CoV-2 under Annex 6, the order to the laboratory must include the information required for electronic invoicing, in particular the tested person’s health insurance number or client number.
4 Persons tested as specified in Annex 6 shall not be required to pay a share of the costs in accordance with Article 64 of the Federal Act of 18 March 199473 on Health Insurance (HIA).
5 Service providers shall not charge persons tested as specified in Annex 6 any additional costs. They must pass on any sums that directly or indirectly cover any part of the cost shares in accordance with Annex 6 to the reimbursement debtor.
6 If the service provider offers services in accordance with Annex 6 that must be paid for by the person tested, it must inform the person concerned before carrying out the test that the costs may be covered under Article 26b.74
71 Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
72 Amended by Annex No 1 of the O of 3 Nov. 2021, in force since 16 Nov. 2021 (AS 2021 653).
73 SR 832.10
74 Inserted by No I of the O of 25 Aug. 2021, in force since 30 Aug. 2021 (AS 2021 507).
1 Where a service involving an analysis for Sars-CoV-2 under Annex 6 number 1 is carried out by a service provider that has a paying agent register number (ZSR number), payment for the service shall be made under the tiers payant system in Article 42 paragraph 2 HIA76 by the following insurers:77
2 Where a service involving an analysis for Sars-CoV-2 under Annex 6 number 1 is carried out by a service provider that does not have a ZSR number, the canton in which the sample is taken shall pay for the services.
3 In the case of analyses for Sars-CoV-2 in accordance with Annex 6 numbers 1.1 and 1.4 following a positive result from a pooled molecular-biological analysis or based on an outbreak investigation ordered by a doctor and in the case of analyses in accordance with Annex 6 numbers 3.1.1 letter a and 3.2.1 letter a, the service providers may choose as the person liable to pay for the service:80
4 Where the analysis for Sars-CoV-2 under Annex 6 Sections 2, 3.1.1 letters b–d and 3.2.1 letters b and c is conducted, the canton in which the sample for Sars-CoV-2 is taken shall pay for the services.81
75 Inserted by No I of the O of 24 June 2020 (AS 2020 2549). Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
76 SR 832.10
77 Amended by No I of the O of 25 Aug. 2021, in force since 1 Oct. 2021 (AS 2021 507).
78 SR 832.12
79 Amended by No I of the O of 1 Oct. 2021, in force since 11 Oct. 2021 (AS 2021 594).
80 Amended by No I of the O of 16 Feb. 2022, in force since 17 Feb. 2022 (AS 2022 96).
81 Amended by No I of the O of 23 June 2021, in force since 26 June 2021 (AS 2021 378).
1 Where an insurer is liable to pay for the service under Article 26a paragraphs 1 and 3 letter a, the service providers under Article 26 paragraph 2 shall send an invoice for services under Annex 6 for each person tested to the insurer concerned on a case-by-case basis or collectively every quarter at the latest nine months after providing the services. The invoice may only cover services under Annex 6. The invoice shall preferably be sent electronically.
2 Service providers shall not charge for services under Annex 6 as Positions 3186.00, 3188.00 and 3189.00 of Annex 3 to the Health Insurance Benefits Ordinance of 29 September 199583 (HIBO).84
3 The insurers shall check the invoices and ascertain whether the service provider has charged correctly for the services under Annex 6. They shall comply with Articles 84–84b HIA85 in processing the data.
4 At the start of January, April, July and October, they shall notify the FOPH of the number of analyses for which they have paid the service providers, and of the amount paid in each case. The external auditors for the insurers shall each year review the figures and confirm that suitable checks in accordance with paragraph 3 are being made and submit a report to the FOPH. The FOPH may request additional information from the insurers on the amounts paid to each service provider.
5 The Confederation shall reimburse the insurers every quarter for the services that they have paid for.
6 If the invoice for the service sent by the service provider is incorrect, the insurer may claim back any payments already made. Once the Confederation has paid for the service in accordance with paragraph 5, the right to reimbursement passes to the Confederation. The insurers shall provide the Confederation with the data required to exercise its right to reimbursement. The data may not include any sensitive personal data.
6bis and 6ter ...86
7 The joint institution shall invoice the FOPH every quarter on a time and material basis for the administrative costs of its activities as an insurer under Article 26a paragraphs 1 letter c and 3 letter a. The hourly rate shall be 95 francs and includes salary costs, social insurance payments and infrastructure costs. The actual costs of any expenditure on audits, system modifications and negative interest not included in the administrative costs shall be reimbursed.
8 Invoices for analyses for Sars-CoV-2 that meet the requirements of Annex 6 must be marked «Analysis for Sars-CoV-2 without meeting the testing criteria».
82 Inserted by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks) (AS 2021 54). Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
84 Amended by No I of the O of 17 Dec. 2021, in force since 18 Dec. 2021 (AS 2021 881).
85 SR 832.10
86 Inserted by No I of the O of 12 May 2021 (AS 2021 274). Repealed by No I of the O of 25 Aug. 2021, with effect from 1 Oct. 2021 (AS 2021 507).
1 Where the canton is liable to pay for the service under Article 26a paragraphs 2, 3 letter b and 4, the service providers shall send a collective invoice on a quarterly basis to the canton concerned no later than nine months after the services were provided. The invoice may only cover services under Annex 6. The invoice shall preferably be sent electronically.
2 Service providers shall not charge for services under Annex 6 as Position 3186.00 of Annex 3 HIBO88.
3 The cantons shall check the invoices and ascertain whether the service provider has charged correctly for the services under Annex 6. They shall comply with the relevant cantonal data protection provisions.
4 At the start of January, April, July and October, they shall notify the FOPH of the number of analyses for which they have paid the service providers, and of the amount paid in each case.
5 The Confederation shall reimburse the cantons every quarter for the services that they have paid for. It shall also make a single start-up payment to cantons that arrange for the targeted and repetitive testing of their residents. The cantons shall invoice the Confederation for the actual costs of such testing only, up to a maximum of 8 francs per resident. Costs related to information technology and logistics may be included.
6 If the invoice for the service sent by the service provider is incorrect, the insurer may claim back any payments already made. Once the Confederation has paid for the service in accordance with paragraph 5, the right to reimbursement passes to the Confederation. The insurers shall provide the Confederation with the data required to exercise its right to reimbursement. The data may not include any sensitive personal data.
87 Inserted by No I of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks) (AS 2021 54). Amended by No I of the O of 12 March 2021, in force since 15 March 2021 (AS 2021 145).
1 In the case of company meetings, the organiser may, regardless of the probable number of participants and without complying with the period of notice for convening meetings, order the participants to exercise their rights exclusively:
2 Notification of the order must be given in writing or published online no later than four days before the event.89
89 Amended by No I of the O of 27 Oct. 2021, in force since 28 Oct. 2021 (AS 2021 634).
90 Inserted by No I of the O of 13 Jan. 2021 (Employees at High Risk) (AS 2021 5). Amended by No I of the O of 17 Dec. 2021, in force from 1 Jan. 2022 until 31 March 2022 (AS 2021 881; Art. 29 para. 7).
1 Employers shall enable their employees at high risk to carry out their working duties from home. They shall take the appropriate organisational and technical measures to achieve this.91
2 Where it is not possible for employees to carry out their regular working duties from home, employers shall, in derogation from the contract of employment and for the same pay, assign the employees concerned equivalent alternative work that can be performed from home.
3 Where for operational reasons the presence of employees at high risk in the workplace is essential at all or at certain times, they may carry out their regular activities in the workplace provided the following requirements are met:
4 If it is not possible for the employees concerned to work in accordance with paragraphs 1–3, the employer shall in derogation from the contract of employment assign them equivalent alternative work in their normal workplace for the same pay in conditions which meet the requirements of paragraph 3 letters a and b.
5 Before the employer takes any measures, he or she shall consult the employees concerned. The employer shall record the measures decided in writing and notify the employees of the same in a suitable manner.
6 The employee concerned may decline to carry out work assigned to him or her if the employer fails to meet the requirements of paragraphs 1–4 or if the employee regards his or her personal risk of infection with the coronavirus for specific reasons as being too high despite the employer taking measures in accordance with paragraphs 3 and 4. The employer may request a medical certificate.
7 If it is not possible for the employee concerned to work in accordance with paragraphs 1–4, or if the employee declines the work assigned in terms of paragraph 6, the employer shall furlough the employee while continuing to pay his or her salary.
8 Employees shall give notice that they are at high risk by making a personal declaration. The employer may request a medical certificate.
9 Article 2 paragraph 3quater of the COVID-19 Loss of Earnings Ordinance of 20 March 202092 governs claims for compensation for loss of earnings related to the corona pandemic.
10 The following persons are regarded as being at high risk:
11 The following persons are not regarded as being at high risk:
12 The diseases and genetic anomalies referred to in paragraph 10 are defined in Annex 7 on the basis of medical criteria. The list of these criteria is not exhaustive. A clinical assessment of the risk in specific cases remains reserved and may lead to persons being classed as being at high risk under paragraph 10bis.
13 The FDHA shall continually update Annex 7 based on the state of science.
14 …96
91 Amended by Annex No 2 of the O of 19 Jan. 2022 (Extension of Measures, Reduction in the Period of Validity of Vaccination and Recovery Certificates, Waiving the Collection of Contact Data, Exemption from the Certificate Requirements for International Delegations, Provisions on the Federal Baccalaureate and Professional Baccalaureate Examinations), in force from 25 Jan. 2022 to 31 March 2022 (AS 2022 21).
92 SR 830.31
93 Amended by No III of the O of 16 Feb. 2022 (Expiry of COVID-19 Certificates only valid in Switzerland), in force from 17 Feb. 2022 to 31 March 2022 (AS 2022 99).
94 SR 818.102.2
95 Amended by Annex No 2 of the O of 19 Jan. 2022 (Extension of Measures, Reduction in the Period of Validity of Vaccination and Recovery Certificates, Waiving the Collection of Contact Data, Exemption from the Certificate Requirements for International Delegations, Provisions on the Federal Baccalaureate and Professional Baccalaureate Examinations), in force from 31 Jan. 2022 to 31 March 2022 (AS 2022 21).
96 Repealed by Annex No 2 of the COVID-19 Special Situation Ordinance of 16 Feb. 2022, with effect from 17 Feb. 2022 (AS 2022 97).
Personal protective equipment that was permitted under Article 24 of the previous law may continue to be placed on the market until 30 June 2021.
98 Inserted by No I of the O of 11 Sept. 2020 (Extension; Test Costs), in force since 18 Sept. 2020 (AS 2020 3695).
1 …100
2 Pharmacies may continue to supply Sars-CoV-2 self-tests licensed under Article 23a of the previous law provided the requirements of Article 24 paragraph 4bis letter b are met.
3 …101
99 Inserted by No I of the O of 23 June 2021, in force since 26 June 2021 (AS 2021 378).
100 Repealed by No I of the O of 16 Feb. 2022, with effect from 17 Feb. 2022 (AS 2022 96).
101 Repealed by No I of the O of 16 Feb. 2022, with effect from 17 Feb. 2022 (AS 2022 96).
102 Inserted by No I of the O of 25. Aug. 2021 (AS 2021 507). Repealed by No I of the O of 16 Feb. 2022, with effect from 17 Feb. 2022 (AS 2022 96).
1 This Ordinance comes into force on 22 June 2020 at 00.00.
2 It applies until 13 September 2020.103
3 ...104
4 The term of application of this Ordinance shall be extended to 31 December 2021, subject to paragraph 5.105
5 Article 27 applies until the provisions on the conduct of general meetings in the Amendment of 19 June 2020106 to the Swiss Code of Obligations107 (Company Law) comes into force, but at the latest until 31 December 2023.108
6 The term of application of this Ordinance shall be extended to 31 December 2022, subject to paragraphs 5 and 7.109
7 Article 27a and Annex 7 apply until 31 March 2022.110
103 Amended by No II of the O of 12 Aug. 2020 (Requirement to wear Masks in Aircraft; Large-scale Events), in force since 15 Aug. 2020 (AS 2020 3547).
104 Repealed by No II of the O of 12 Aug. 2020 (Requirement to wear Masks in Aircraft; Large-scale Events), with effect from 15 Aug. 2020 (AS 2020 3547).
105 Inserted by No I of the O of 11 Sept. 2020 (Extension; Test Costs) (AS 2020 3695). Amended by No I of the O of 27 Oct. 2021, in force since 28 Oct. 2021 (AS 2021 634).
106 AS 2020 4005
107 SR 220
108 Inserted by No I of the O of 27 Oct. 2021, in force since 28 Oct. 2021 (AS 2021 634).
109 Inserted by No I of the O of 17 Dec. 2021, in force since 1 Jan. 2022 (AS 2021 881).
110 Inserted by No I of the O of 17 Dec. 2021, in force since 1 Jan. 2022 (AS 2021 881).
111 Amended by No I of the FDJP O of 20 Jan. 2022, in force since 24 Jan. 2022 (AS 2022 26).
(Art. 3 para. 3, 4 para. 2ter and Art. 5)
All countries and regions outside the Schengen area, with the exception of:
There are no entries currently on this list
112 Inserted by Annex 3 of the COVID-19 Ordinance on International Travel Measures of 23 June 2021 (AS 2021 380). Revised in accordance with Annex No 3 I of the O of 17 Sept. 2021 (AS 2021 563) and by Annex No 2 of the O of 19 Jan. 2022 (Extension of Measures, Reduction in the Period of Validity of Vaccination and Recovery Certificates, Waiving the Collection of Contact Data, Exemption from the Certificate Requirements for International Delegations, Provisions on the Federal Baccalaureate and Professional Baccalaureate Examinations), in force from 31 Jan. 2022 (AS 2022 21).
(Art. 4 para. 2 let. a and Art. 5)
113 SR 818.102.2
114 Rendered obsolete by the repeal of Art. 8 (see Art. 6 No 1 of the COVID-19 Ordinance on International Travel Measures of 2 July 2020, AS 2020 2737).
115 Amended by No I of the FDJP O of 27 Nov. 2021 (AS 2021 780). Revised by No III of the O of 3 Dec. 2021, in force since 4 Dec. 2021 (AS 2021 814).
(Art. 9 para. 3)
There are no entries currently on this list.
116 Amended by No I of the FOPH O of 6 Oct. 2020 (List of important medical products and list of active substances for the treatment of COVID-19) (AS 2020 4129). Revised by No II para. 1 of the O of 27 Jan. 2021 (Tests for Sars-CoV-2 and FFP Masks) (AS 2021 54), No I para. 1 of the FDHA O of 14 April 2021 (Amendment of the lists of important medical products and of active substances for the treatment of COVID-19 (AS 2021 212), No II of the O of 12 May 2021 (AS 2021 274), No I of the FDHA O of 17 Aug. 2021 (Amendment of the List of important medical products and list of active substances for the treatment of COVID-19), in force since 25 Aug. 2021 (AS 2021 493) and No I para. 1 of the FDHA O of 19 Jan. 2022 (Amendment of the List of important medical products and list of active substances for the treatment of COVID-19), in force since 21 Jan. 2022 (AS 2022 23).
(Art. 11 para. 1, 19 para. 1 and 21 para. 2)
1. Tocilizumab
2. Remdesivir
3. Propofol
4. Midazolam
5. Ketamine
6. Dexmedetomidine
7. Dobutamine
8. Sufentanil
9. Remifentanyl
10. Rocuronium
11. Atracurium
12. Suxamethonium
13. Noradrenalin
14. Adrenalin
15. Insulin
16. Fentanyl
17. Heparin
18. Argatroban
19. Morphine
20. Paracetamol (parenteral)
21. Metamizol (parenteral)
22. Lorazepam
23. Dexamethasone
24. Co-Amoxicillin
25. Piperacillin/Tazobactam
26. Meropenem
27. Imipenem/Cilastatin
28. Cefuroxime
29. Ceftriaxone
30. Amikacin
31. Posaconazole
32. Fluconazole
33. Voriconazole
34. Caspofungin
35. Esmolol (parenteral)
36. Metoprolol (parenteral)
37. Labetalol (parenteral)
38. Clonidine
39. Amiodarone
40. Furosemide
41. Vaccines against COVID-19
42. Vaccines against influenza
43. Vaccines against bacterial pneumonia (Prevnar 13)
44. Medical gases
46. Nirmatrelvir/Ritonavir
47. Medical oxygen
48. Infusion solutions
49. Sotrovimab
117 SR 812.213
1. Ventilators
2. Monitoring equipment for intensive care
3. In vitro diagnostics (COVID-19 tests), including pre-analytical components and instruments
4. Surgical masks / OP masks (hygiene masks)
5. Surgical gloves / examination gloves
6. Infusion sets
7. Pipette tips with filters
8. Test kits (tubes and swabs)
9. Single-use syringes and cannulae
10. Blood gas syringes
118 SR 930.115
1. Respirators (FFP2 and FFP3)
2. Aprons
3. Protective overalls
4. Protective eyewear
5. Disposable caps
1. Hand disinfectants
2. Surface disinfectants
3. Ethanol
4. Hygiene products for intensive care (such as absorbent pads, diapers, faecal collectors, oral hygiene items)
119 Amended by No I para. 2 of the FDHA O of 19 Jan. 2022 (Amendment of the List of important medical products and list of active substances for the treatment of COVID-19), in force since 21 Jan. 2022 (AS 2022 23).
(Art. 21 paras 1 and 3, as well as 22 para. 1)
120 Inserted by No III para. 1 of the O of 18 Dec. 2020 (Sars-CoV-2 Rapid Tests) (AS 2020 5801). Repealed by No II para. 1 of the O of 25 Aug. 2021, with effect from 30 Aug. 2021 (AS 2021 507).
121 Inserted by No II of the O of 28 Oct. 2020 (Sars-CoV-2 Rapid Antigen Tests) (AS 2020 4495). Amended by No III of the O of 12 March 2021 (AS 2021 145). Revised by No II of the O of 12 May 2021 (AS 2021 274), of 23 June 2021 (AS 2021 378), the correction dated 29 June 2021 (AS 2021 407), Annex No 3 I of the O of 17 Sept. 2021 (AS 2021 563), No II para. 2 of the O of 25 Aug. 2021 (AS 2021 507), No II of the O of 1 Oct 2021 (AS 2021 594), Annex No 1 of the O of 3 Nov. 2021 (AS 2021 653), No II para. 1 of the O of 17 Dec. 2021 (AS 2021 881), No III 1 of the O of 2 Feb. 2022 (Lifting the Requirement for Contact Quarantine and to Work from Home) (AS 2022 59), No I of the O of 4 Feb. 2022 (AS 2022 65) and No II of the O of 16 Feb. 2022, in force since 17 Feb. 2022 (AS 2022 96).
(Art. 26, 26a, 26b and 26c)
Service | Maximum amount |
Patient consultation and taking sample, including protective materials | 22.50 Fr. |
For supervising the taking of the sample by the person tested and assigning the sample to the person concerned | 15 Fr. |
Reporting the test result to the person tested and to the responsible authorities under Article 12 paragraph 1 EpidA, and requesting the activation code generated by the Proximity Tracing System for the Coronavirus Sars-CoV-2 (PT System) when infection is detected and for issuing the COVID-19 test or recovery certificate | 2.50 Fr. |
Detailed doctor-patient consultation on the indications, where such is carried out | 22.50 Fr. |
Service | Maximum amount |
If conducted on behalf of another service provider, comprising:
| |
| 82 Fr. |
| 74 Fr. |
| 70 Fr. |
| 64 Fr. |
| |
If conducted without being requested by another service provider, comprising:
| 87 Fr. |
| 82 Fr. |
| 74 Fr. |
| 70 Fr. |
| 64 Fr. |
| 5 Fr. |
Service | Maximum amount |
Patient consultation and taking sample, including protective materials | 22.50 Fr. |
For supervising the taking of the sample by the person tested and assigning the sample to the person concerned | 15 Fr. |
Service | Maximum amount |
If conducted on behalf of another service provider, comprising: | 274 |
| |
| |
| |
If conducted without being requested by another service provider, comprising: | |
| |
| |
| |
Service | Maximum amount |
When conducted at compulsory school level and at upper secondary level in cases under Number 1.2.1 for the creation of each pool | 18.50 Fr. |
Service | Maximum amount |
Patient consultation and taking sample, including protective materials | 22.50 Fr. |
Reporting the test result to the person tested and to the responsible authorities under Article 12 paragraph 1 EpidA | 2.50 Fr. |
Detailed doctor-patient consultation on the indications, where such is carried out | 22.50 Fr. |
Service | Maximum amount |
If conducted on behalf of another service provider, comprising: | 49 Fr. |
| 25 Fr. |
| 24 Fr. |
If conducted without being requested by another service provider, comprising: | 30 Fr. |
| 25 Fr. |
| 5 Fr. |
Service | Maximum amount |
Patient consultation and taking sample, including protective materials | 22.50 Fr. |
Reporting the test result to the person tested and to the responsible authorities under Article 12 paragraph 1 EpidA and requesting the activation code generated by the PT system when infection is detected and for issuing the COVID-19 test or recovery certificate | 2.50 Fr. |
Detailed doctor-patient consultation on the indications, where such is carried out | 22.50 Fr. |
Service | Maximum amount |
If carried out without being requested by another authorised service provider, comprising: | 11 Fr. |
| 6 Fr. |
| 5 Fr. |
If carried out on behalf of another authorised service provider, comprising: | 30 Fr. |
| 6 Fr. |
| 24 Fr. |
Service | Maximum amount |
If carried out without being requested by another authorised service provider, for the analysis and report to the authorities under Article 12 paragraph 2 EpidA | |
If carried out on behalf of another service provider, comprising: | |
| |
| |
Service | Maximum amount |
Conduct of the analysis, comprising: | 221 Fr. |
| |
| |
Service | Maximum amount |
For supervising the taking of the sample by the person tested and assigning the sample to the person concerned | 15 Fr. |
For reporting the test result to the person tested and issuing the COVID-19 test certificate | 2.50 Fr. |
Service | Maximum amount |
If carried out on behalf of another authorised service provider, comprising: | 16 |
| |
| 3 |
If carried out on behalf of another authorised service provider, comprising: | |
| 13 Fr. |
| |
Service | Maximum amount |
For organising the pool, per person | 2.50 Fr. |
Service | Maximum amount |
If the sample is not taken by the tested person him- or herself: taking the sample and conducting a test, including the test materials, the protective materials and working time, and for the analysis and order processing | 28 Fr. |
If the sample is taken by the tested person him- or herself: taking the sample and conducting a test, including the test materials, the protective materials and working time, and for the analysis and order processing | 14 Fr. |
For issuing the COVID-19 test or recovery certificate | 2.50 Fr. |
Service | Maximum amount |
Taking the sample, including the protective materials and working time | 16.50 Fr. |
Service | Maximum amount |
If conducted on behalf of another service provider, comprising: | 274 Fr. |
| |
| |
| |
If conducted without being requested by another service provider, comprising: | 255 Fr. |
| |
| |
| |
Service | Maximum amount |
When conducted at compulsory school level, at upper secondary level and at school camps, for the creation of each pool | 18.50 Fr. |
Service | Maximum amount |
For issuing the COVID-19 test certificate | 2.50 Fr. |
Service | Maximum amount |
Conducting the Sars-CoV-2 rapid test for specialist use, test materials only | 6.00 |
For issuing the COVID-19 test or recovery certificate | 2.50 Fr. |
s |
Service | Maximum amount |
If conducted on behalf of another service provider, comprising: | |
| |
| |
| |
If conducted without being requested by another service provider, comprising: | |
| |
| |
| |
For issuing the COVID-19 test certificate | 2.50 Fr. |
125 In force until 30 Sept. 2021 (AS 2021 507).
126 Inserted by No II of the O of 13 Jan. 2021 (Employees at High Risk), in force from 18 Jan. 2021 to 31 Dec. 2021 (AS 2021 5) (AS 2021 5). Amended by No II para. 1 of the O of 17 Dec. 2021, in force from 1 Jan. 2022 until 31 March 2022 (AS 2021 881; Art. 29 para. 7).
(Art. 27a para. 10 let. b, 12 and 13 and Art. 29 para. 7)
According to the current state of science, a high risk can only be assumed for certain categories of adult person. The following criteria therefore apply to adults only.
Die auf dieser Website abrufbaren Gesetze und Dokumente sind keine amtlichen Veröffentlichungen. Massgebend sind allein die Veröffentlichungen durch die Bundeskanzlei. Siehe www.fedlex.admin.ch.
In Bezug auf englische Sprachfassungen sei darauf hingewiesen, dass Englisch keine offizielle Amtssprache ist. Die englischen Übersetzungen der Erlasstexte dienen lediglich der generellen Information.
Bitte beachten Sie, dass sich die Website in Entwicklung befindet und gegenwärtig in einer Beta-Version vorliegt. Es können entsprechend Fehler auftauchen oder die Website ist über gewisse Zeit nicht oder nur eingeschränkt verfügbar.
Eine Übersicht zum Entwicklungsstand und den momentan verfügbaren Funktionen finden Sie hier.
Die Website ist aktuell nicht vollständig für den Zugriff via Mobile-Geräte optimiert. Es wird daher empfohlen, die Website auf einem Laptop oder Desktop-PC aufzurufen.
Es sei im Weiteren auf die Hinweise in den Nutzungsbedingungen verwiesen.
Tour durch die Funktionen gefällig?